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Cysteine  string  protein  (CSP)  is a  member  of the  DnaJ/Hsp40  family  of  co-chaperones  that  localises  to
neuronal  synaptic  vesicles.  Its  name  derives  from  the possession  of a string  of  12–15 cysteine  residues,
palmitoylation  of  which  is  required  for  targeting  to  post-Golgi  membranes.  The  DnaJ  domain  of  CSP
enables  it to bind  client  proteins  and  recruit  Hsc70  chaperones,  thereby  contributing  to the  mainte-
nance  of protein  folding  in  the presynaptic  compartment.  Mutation  of  CSP  in ﬂies, worms  and  mice
reduces  lifespan  and  causes  synaptic  dysfunction  and  neurodegeneration.  Furthermore,  recent  studies
have revealed  that  the  neurodegenerative  disease,  adult  onset  neuronal  ceroid  lipofuscinosis,  is caused
by mutations  in the  human  CSP-encoding  DNAJC5  gene.  Accumulating  evidence  suggests  that  the  majoresveratrol mechanism  by which  CSP  prevents  neurodegeneration  is by maintaining  the  conformation  of  SNAP-
25,  thereby  facilitating  its  entry into  the membrane-fusing  SNARE  complex.  In this  review,  we focus
on  the  role  of  CSP  in preventing  neurodegeneration  and  discuss  how  recent  studies  of this  universal
neuroprotective  chaperone  are  being  translated  into  potential  novel  therapeutics  for  neurodegenerative
diseases.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
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. Introduction: discovery and properties of CSPs that the antibody recognised proteins encoded by three splice vari-Cysteine string protein (CSP) was ﬁrst discovered in Drosophila
elanogaster based on the use of a neuronal-speciﬁc monoclonal
ntibody that labelled nerve terminals. Cloning of cDNA revealed
Abbreviations: ANCL, adult onset neuronal ceroid lipofuscinosis; CREB, cAMP
esponse element binding protein; CSP, cysteine string protein; GABA, gamma-
mino butyric acid; SGT, small glutamine-rich tetratricopeptide repeat-containing
rotein; SNAP-25, synaptosome-associated protein of 25-kDa; SNAREs, soluble NSF
ttachment protein receptors; VAMP, vesicle associated membrane protein.
∗ Corresponding author. Tel.: +44 151 794 5333; fax: +44 151 794 5337.
E-mail address: amorgan@liverpool.ac.uk (A. Morgan).
ttp://dx.doi.org/10.1016/j.semcdb.2015.03.008
084-9521/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uants of a novel gene. These were distinguished by the presence of
a string of 11 contiguous cysteine residues leading to the naming
of the protein(s) as cysteine string protein [1]. Soon after, a CSP
was also discovered in Torpedo californica following an attempt to
identify possible subunits of neuronal calcium channels, which at
that time had not been identiﬁed or molecularly characterised [2],
and it was  shown to be localised to synaptic vesicles [3]. CSPs were
soon identiﬁed in mammalian species [4–6]. The Torpedo protein
[7] and subsequently CSPs in other species were found to be exten-
sively palmitoylated on their cysteine residues. Palmitoylation was
shown to determine the membrane association of CSPs [8–10] and
the enzymatic basis for palmitoylation of CSP has been extensively
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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1ig. 1. Domain structure of human CSP. The locations of the Serine10 phosphoryl
ndicated. The leucine residues mutated in ANCL patients are highlighted by asteris
tudied [11–16]. In addition to being expressed in multiple species,
SP was also found to be present on a wide range of types of secre-
ory vesicles in neuronal and non-neuronal tissues [5,6,17–19].
nvertebrates such as Drosophila and Caenorhabditis elegans have
nly a single CSP-encoding gene (Csp and dnj-14,  respectively);
hereas mammals express three CSP proteins (, , ) that are
ncoded by the DNAJC5a, b and g genes. CSP and CSP are highly
omologous throughout their amino acid sequences, but CSP is
ore distantly related [20]. CSP is the major protein expressed in
ost cells and virtually all neurons. In contrast, mammalian CSP
nd CSP are expressed only in testis [21,22], with the exception
hat CSP is uniquely also expressed in auditory hair cell neurons
23,24]. The functional roles of CSP and CSP are unknown.
The sequence of CSP revealed that it contains a conserved J
omain (Fig. 1) and so it is a member of the DnaJ/Hsp40 family of
o-chaperones. CSP has a characteristic HPD motif in the J-domain
hat is required in this family of proteins to allow them to bind to
sc70/Hsp70 and act in concert with Hsc70/Hsp70 in the refolding
r disaggregation of client proteins. Biochemical analysis of CSP
emonstrated that it could indeed bind to and activate the ATPase
ctivity of Hsc70 [25,26] and also that it could reverse aggregation
f model substrates in conjunction with Hsc70 [27]. It was  subse-
uently suggested that CSP and Hsc70 function along with small
lutamine-rich tetratricopeptide repeat-containing protein (SGT)
n a trimeric complex [28,29]. While CSP is clearly able to bind to
GT, there are doubts about the physiological signiﬁcance of the
GT interaction. These stem from the fact that the interaction of SGT
ith CSP characterised in vitro with recombinant proteins and via
he yeast 2-hybrid method occurs through the non-palmitoylated
ysteine-string domain [29], which would not be available for
nteraction in vivo. Recently it has been established that SGT is
 chaperone for the transmembrane region of tail-anchored pro-
eins [30,31], suggesting that SGT binding to recombinant CSP
n vitro may  be a consequence of its artefactual recognition of the
ydrophobic cysteine rich region due to its similarity to a bona ﬁde
ransmembrane domain.
. Which proteins are substrates for refolding by the
ynaptic chaperone CSP?
Early efforts to discover potential clients for CSP identiﬁed mul-
iple direct protein interactions including with syntaxin [32–34],
AMP [35,36], G protein subunits [37,38], Rab-GDI [39], mutant
untingtin [40,41], the 1B subunit of N-type calcium channels
37,42], the 1A subunit of P/Q type calcium channels [43] and
ynaptotagmins [44,45]. The observed reduction of SNAP-25 in
SP knock out mice led to the identiﬁcation of this protein as a
otential CSP client [46]. More recent work has attempted to iden-
ify novel CSP clients by using an unbiased proteomic approach
earching for any proteins down-regulated in the brains of CSP
nock-out mice. This resulted in the identiﬁcation of 10 chap-
rones and 27 additional down-regulated proteins that included
NAP-25 [47]. The identiﬁcation of one novel CSP client, dynamin
, was conﬁrmed in direct binding assays and a role for CSP insite, the HPD motif in the J domain, and the cysteine-rich region of the protein are
dynamin-mediated synaptic vesicle recycling was described in
another study [48].
3. Cellular functions of CSP
Information on the functional importance of CSP came initially
from analysis of Csp mutants in Drosophila. The ﬁrst of the papers on
these mutants provided key evidence supporting the now accepted
role of CSP as a neuroprotective chaperone at the synapse [49–51].
In this work it was found that loss of CSP expression resulted in very
rapid death of adult ﬂies, by 5 days at 22 ◦C and within 1 h at 29 ◦C,
and the ﬂies showed evidence of synaptic degeneration observed by
electron microscopy [52]. The follow-up analyses of these mutant
ﬂies focused to a large extent on studying the phenotype of the
few adult survivors (95% of Csp null mutants die during develop-
ment) and in particular there was  an emphasis on what was  seen
as the “temperature-dependent” aspects of the phenotypes, where
the ﬂies rapidly became paralysed at elevated temperature [53],
rather than the causes of the rapid neurodegeneration and death.
Electrophysiological analysis of synaptic function in Csp mutant
ﬂies suggested that CSP was required for normal synchronous
evoked neurotransmitter release [54,55], but this did not appear
to be related to any effect on presynaptic calcium channel func-
tion [56]. In addition, the ﬂies showed various defects in calcium
handling or calcium coupling to exocytosis [57–60]. Studies on
non-neuronal cells, examining the effects of CSP overexpression
suggested a direct role for CSP in regulated exocytosis [61–64].
The ability of CSP to interact with its client proteins syntaxin or
synaptotagmin in vitro was  found to be modulated by its phos-
phorylation on Serine10 [44,65] and this phosphorylation allows
interaction of CSP with 14-3-3 protein [66]. Ser10 phosphorylation
on CSP appears to be constitutive within neuronal tissues [67–69],
although the extent of phosphorylation varies greatly between
neighbouring GABAergic and glutamatergic synapses within the
same region of the cerebellum [67]. The effects of CSP over-
expression on the late stages of regulated exocytosis are modulated
by its phosphorylation on Ser10 [65,70,71].
4. CSP and neurodegeneration
The key neuroprotective role of CSP was apparent in the ﬂy
mutants but only rose to prominence in considerations of the func-
tion of the protein following analysis of CSP knock-out mice. For
the ﬁrst few weeks of life, these mice appeared normal and did not
show defects in neurotransmission [22], but then developed a pro-
gressive sensorimotor disorder, evidence of neurodegeneration in
neuromuscular junctions and calyx synapses and died at around 8
weeks of age. These mice also showed extensive and rapid degen-
eration of retinal photoreceptors [23] and hippocampal GABAergic
neurons were found to be differentially sensitive to the absence
of CSP compared to glutamatergic neurons [72]. The high sensi-
tivity of GABAergic neurons was attributed to their high levels of
synaptic activity, which is consistent with the more rapid degener-
ation seen in tonically active ribbon synapses of photoreceptor cells
ll & Developmental Biology 40 (2015) 153–159 155
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Fig. 2. Chaperoning of SNAP-25 by CSP and Hsc70 at the synapse. A typical synaptic
vesicle containing approximately three molecules of CSP [77] is represented. Binding
of  Hsc70 to SNAP-25 is thought to recruit CSP, thereby altering the conformation
of  SNAP-25, facilitating its entry onto the SNARE complex that drives membrane
fusion. Direct binding is indicated by double-headed arrows. Structures of SNAP-25
(3IPD), and hsc70/DnaK (2KHO) were obtained from the Brookhaven protein data
bank. The CSP structure prediction was generated by I-TASSER. Residues involvedR.D. Burgoyne, A. Morgan / Seminars in Ce
ompared to other retinal synapses [23]. More detailed analysis of
he mice revealed additional defects in synaptic function including
 reduction in the normal calcium sensitivity of the neurotrans-
itter release mechanism [73] and also an impairment of synaptic
esicle recycling at the neuromuscular junction [48]. These latter
ndings would ﬁt with the existence of multiple client proteins for
SP including dynamin 1.
The evolutionary conservation of CSP’s neuroprotective func-
ion is underlined by a recent study of the C. elegans CSP orthologue,
hich is known as DNJ-14. The phenotypes of dnj-14 null mutant
orms show remarkable similarities to CSP knockout mice in that
oung animals are virtually indistinguishable from wild-type, but
xhibit progressive neuronal dysfunction and neurodegeneration
ith increasing age and have a reduced lifespan [24]. It is not clear
hy complete loss of CSP in Drosophila causes ∼95% embryonic
ethality, whereas no major effects on fertility or initial viabil-
ty are observed in knockout worms and mice, but perhaps this
eﬂects some speciﬁc functions of CSP during ﬂy development.
eurodegeneration in aged C. elegans dnj-14 mutants preferentially
ffects sensory neurons and indeed these animals exhibit severely
mpaired chemosensory neuron function before neurodegenera-
ion becomes apparent [24]. This progression from early functional
ynaptic defects leading on to later structural alterations and neu-
onal death is reminiscent of many neurodegenerative diseases and
uggests that the dnj-14 worm model may  be useful for identifying
enerally neuroprotective mechanisms and therapies. However,
he surprising observation that loss of CSP is actually neuroprotec-
ive in a Drosophila model of injury-induced axonal degeneration
74] suggests that some acute neurodegeneration models could
nvolve distinct mechanisms that may  not be ameliorated by CSP’s
therwise universal neuroprotective function.
A surprising ﬁnding was that the neurodegeneration and
educed life-span in CSP KO mice was signiﬁcantly reversed by
verexpressing -synuclein [46]. Both wild-type and a disease-
elated mutant (A30P) -synuclein had positive effects although
hat of the wild-type protein was more marked. Conversely, the
SP KO phenotype was exacerbated by knock-out of - or -
ynuclein [46]. Analysis of CSP KO mice expressing the A30P
utant version of -synuclein revealed that these mice show
ncreased synaptic function consistent with a protective function
ven of this pathogenic form of -synuclein [75]. A further impor-
ant observation from the study of CSP KO mice and -synuclein
verexpression was that the absence of CSP resulted in a reduc-
ion in SNAP-25 levels and a corresponding reduction in the levels
f assembled SNARE complexes [46]. The loss of SNAP-25 was not
ffected by overexpression of -synuclein. In contrast, wild type
ut not A30P -synuclein reversed the reduction in SNARE com-
lexes suggesting that this may  contribute, at least in part, to the
rotective effect of -synuclein. A further link between -synuclein
nd CSP was shown in a study examining the effects of exogenous
-synuclein or a -amyloid peptide on cultured hippocampal neu-
ons where both treatments were observed to result in a reduction
n levels of CSP expression [76].
It may  seem surprising that SNAP-25 has been identiﬁed as
 potential client for CSP, as CSP is primarily a synaptic vesi-
le protein whereas SNAP-25 is largely localised to the axonal
lasma membrane (Fig. 2). Furthermore, CSP is expressed at rel-
tively low levels (2.8 molecules per synaptic vesicle and 941
olecules per synapse, on average) compared to the very abundant
NAP-25 (26,686 molecules per synapse) [77,78]. This raises some
nteresting mechanistic questions, as presumably only SNAP-25
olecules in the immediate proximity of tethered/docked vesi-
les at the active zone would be close enough to be chaperoned by
SP/Hsc70. Perhaps this forms a useful checkpoint system, ensur-
ng that the energy of ATP hydrolysis by Hsc70 is only expended on
riming SNAP-25 molecules that can form a local SNARE complexin Hsc70 binding (HPD motif, blue), synaptotagmin binding (E93, yellow), and the
serine-10 phosphorylation site (green) are highlighted as spheres. All structures
were rendered using UCSF chimaera.
and so drive membrane fusion. Nevertheless, it remains unclear
how CSP prevents proteasomal degradation of the majority of the
cellular pool of SNAP-25 despite its substrate being >25-fold in
excess and mostly localised away from the active zone where CSP
binding could potentially occur.
Notwithstanding these questions, detailed analysis of the
CSP knock-out mice has strongly suggested that SNAP-25 is
the major client for CSP, that CSP stimulates SNARE complex
assembly and that neurodegeneration in the absence of CSP
can be explained by defective SNAP-25 function [79,80]. The
work of Sharma et al. [79] showed that in the absence of CSP
SNAP-25 is selectively decreased due to its ubiquitination and
its proteolysis in an activity-dependent manner. Moreover, CSP
over-expression increased SNAP-25 levels. In vitro binding exper-
iments suggested that CSP did not bind directly to SNAP-25, but
did so indirectly via Hsc70. This is unusual as J domain proteins
usually bind the client protein directly and then subsequently
recruit Hsc70. In an additional study exploring synuclein function
it was found that the absence of the synucleins reduced the
ability of the SNAREs to assemble into SNARE complexes and that
-synuclein directly stimulated SNARE complex assembly in vitro.
This required the direct binding of -synuclein to VAMP. These
ﬁndings could explain the earlier ﬁnding [46] that over-expression
of -synuclein compensates for the loss of CSP and thereby
SNAP-25. A key question at this point was whether the effect of
CSP absence on SNAP-25 levels or on its folding is the cause of
neurodegeneration in the CSP knock-out mice. One possibility
was that it is not the reduction in SNAP-25 levels themselves that
leads to synaptic dysfunction and subsequent neurodegeneration,
but the accumulation of aberrantly folded forms of SNAP-25 that
undergo abnormal protein interactions or that other CSP clients
were involved [81]. This issue of the link between SNAP-25 and
neurodegeneration was further addressed leading to the ﬁnding
that decreased SNAP-25 levels worsened the CSP knock-out
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henotype reducing life-span and levels of assembled SNARE
omplexes and exacerbated neurodegeneration [80]. An increase
f SNAP-25 levels using lentiviral expression rescued the CSP
nock-out phenotype with neurodegeneration (neuronal loss)
eing reversed in brain regions over-expressing SNAP-25. These
ndings are consistent with SNAP-25 being the main CSP client
hose loss leads to neurodegeneration in the absence of CSP.
. CSP and human neurodegenerative disease
Despite the compelling evidence for an essential role of CSP in
reventing neurodegeneration in animal models, a direct link to
uman disease was established only recently. Between 2011 and
013, four independent research groups reported an association
etween mutations in the CSP-encoding DNAJC5 gene and adult
nset neuronal ceroid lipofuscinosis (ANCL), using a combination
f whole exome sequencing, linkage analysis and candidate gene
esequencing [82–85]. ANCL, also known as autosomal dominant
ufs’ disease and Parry disease, is a very rare hereditary neu-
odegenerative disorder. It presents with broad clinical variability,
lthough common signs include generalised epilepsy, movement
isorders and progressive dementia. The disease has a mean age
f onset of 30 years and progresses rapidly upon diagnosis, with
eath occurring on average at 45 years of age [85]. Pathologically,
NCL is associated with intra-neuronal inclusions of autoﬂuo-
escent lipofuscin-like material and neurodegeneration, hence its
lassiﬁcation as one of the neuronal ceroid lipofuscinoses, which is
 large genetically heterogeneous class of neurodegenerative disor-
ers deﬁned by these two essential features [86,87]. However, the
isual system tends to be unaffected by neurodegeneration in ANCL,
n contrast to most other NCLs that are generally associated with
lindness [85,86]. Given its rarity and clinical variability, ANCL is
ften misdiagnosed [83], so it is important that several independent
roups identiﬁed the same DNAJC5 mutations in different patient
roups, leaving little doubt that these mutations cause ANCL.
Interestingly, all ANCL patients studied to date harbour one of
wo mutations in the coding sequence for the cysteine string motif,
esulting in either a deletion of leucine116 or a leucine115-arginine
ubstitution [82–85] (see Fig. 1). Given the known requirement of
he cysteine string domain for palmitoylation [7,9,10] and for tar-
eting to post-Golgi membranes [9], this immediately suggested
hat the mutant proteins may  be inefﬁciently targeted to synap-
ic vesicles. Indeed, the original report by Noskova et al. [82]
howed that recombinant GFP-tagged CSP mutant constructs
ere retained in an abnormal cell body localisation co-migrating
ith endoplasmic reticulum and Golgi markers, in contrast to wild
ype GFP-CSP that was efﬁciently transported to the plasma mem-
rane. Consistent with such a targeting defect, post-mortem brain
amples from ANCL patients similarly showed a large reduction in
ynaptic CSP levels compared to controls [82]. These ﬁndings were
ndependently conﬁrmed and extended by Greaves et al. [88], who
emonstrated that the ANCL mutations induce aggregation into
DS-resistant palmitoylated aggregates. Importantly, Greaves et al.
sed a dual epitope tagging system to reveal that wild type CSP
an co-aggregate with mutant CSP [88], a ﬁnding that has recently
een conﬁrmed [89], thereby potentially explaining the dominant
ffect of the mutations and the otherwise puzzling observation that
NCL patients lack synaptic CSP protein despite carrying one wild
ype DNAJC5 allele.
Although ANCL is the only disease known to be caused by
SP mutations, alterations in the levels or activity of CSP could
otentially impact on other neurodegenerative conditions given
ts neuroprotective function. One clue is the ﬁnding that CSP can
nteract with mutant huntingtin containing an expanded polyQ
omain but not the wild type protein in vitro [40]. This was con-
rmed in a proteomic study of mouse brain [41] but its relevanceevelopmental Biology 40 (2015) 153–159
to the progress of Huntington’s disease is still to be established.
In addition, it has recently been reported that expression of CSP
is reduced in degenerating areas of the forebrain in post-mortem
samples of Alzheimer’s patients [90]. It appears that this is not
simply a consequence of reduced synaptic vesicle number, as the
integral synaptic membrane protein marker, synaptophysin, did
not exhibit equivalent reduced expression. Interestingly, the reduc-
tion of CSP expression is restricted to degenerating brain areas,
with levels actually being increased in non-degenerating cerebellar
tissue from the same patients [90]. Note, however, that heterozy-
gous CSP KO mice, which contain half the normal CSP protein
level, do not show any difference in susceptibility to prion dis-
ease in the ME7  model [91]. Nevertheless, a further connection
between CSP and more common forms of neurodegeneration
comes from the observation that SNARE complex levels are reduced
in post-mortem brain samples from both Alzheimer’s and Parkin-
son’s disease patients [92]. Given the role of CSP in facilitating
SNARE complex assembly discussed earlier, it is tempting to specu-
late that the reduced levels of SNARE complexes are a consequence
of impaired CSP chaperone activity. Clearly, it is important that
further studies of post-mortem tissue from a variety of neurodegen-
erative diseases are performed to establish if altered CSP activity
and/or SNARE complex assembly represent common underlying
features of neurodegeneration.
6. Therapeutic implications
CSP is expressed in all synapses and prevents neurodegen-
eration in worms, ﬂies, mice and humans. It therefore appears
to be a generally neuroprotective chaperone protein. Drugs that
could either increase CSP activity or bypass the requirement
for CSP thus represent potential therapies – not only for ANCL,
but also more generally for neurodegenerative diseases. Indeed,
recent work has begun to identify compounds that can compen-
sate for the lack of functional CSP in animal models. Treatment
of CSP knock-out mice with proteasome inhibitors was found
to result in increased life-span and a delay in neurodegenera-
tion [92]. This striking result is at ﬁrst glance surprising, as one
widely proposed therapeutic strategy for protein misfolding dis-
orders that lead to neurodegeneration is to increase the activity
of the ubiquitin-proteasome system that degrades the misfolded
protein(s). It might be expected, therefore, that proteasome inhibi-
tion would exacerbate neurodegeneration in CSP knock-out mice.
The fact that the reverse is true was attributed to an observed
increase in SNAP-25 levels and in assembled SNARE complexes
through prevention of SNAP-25 degradation by the proteasome
[92]. Furthermore, Sharma et al. showed that the reduced levels
of assembled SNARE complexes that ultimately cause neurodegen-
eration in CSP knock-out mice are also evident in post-mortem
brain samples from Alzheimer’s and Parkinson’s disease patients
[92]. Proteasome inhibitors may  therefore have therapeutic appli-
cations for these common neurodegenerative diseases as well as
for ANCL.
A recent chemical screen revealed that resveratrol can rescue
the short lifespan, chemosensory impairment and neurodegenera-
tion phenotypes of C. elegans dnj-14 null mutants [24]. Resveratrol
is a plant-derived polyphenolic compound found in various
foodstuffs, notably red wine, which has well-documented cardio-
protective, anti-inﬂammatory, anti-tumour and neuroprotective
properties [93]. Its mechanism of action is the subject of consider-
able debate, although most attention has focused on resveratrol’s
ability to activate the Sirtuin class of NAD+-dependent histone
deacetylases, notably SIRT1. However, rescue of the dnj-14 pheno-
types by resveratrol was unaffected by deletion of the worm SIRT1
orthologue, sir-2.1,  suggesting a Sirtuin-independent mechanism
R.D. Burgoyne, A. Morgan / Seminars in Cell & D
Fig. 3. Resveratrol and rolipram rescue the short lifespan of C. elegans dnj-14
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ain  a large deletion in the worm orthologue of CSP, in the presence and absence of
rugs; and also on the corresponding wild type strain (Bristol N2).
f action. It has been suggested that resveratrol is a competitive
nhibitor of cAMP phosphodiesterases [94]. This is consistent with
he observation that rolipram (a structurally unrelated cAMP phos-
hodiesterase inhibitor with neuroprotective properties [95,96])
imilarly rescued dnj-14 phenotypes (Fig. 3) [24]. Furthermore,
orskolin, which increases cAMP levels via activation of adenylate
yclase rather than phosphodiesterase inhibition, ameliorates the
euromuscular transmission defects in CSP knock-out mice [48].
t is tempting to speculate that increased cAMP signalling activates
lternative CSP-independent pathways that facilitate SNARE com-
lex formation, thereby compensating for the lack of CSP in these
nimal models. Indeed, phosphorylation of SNAP-25 and other
ynaptic exocytosis proteins by cAMP-dependent protein kinase is
nown to increase SNARE-dependent neurotransmission [97,98].
lternatively, it may  be that cAMP acts via longer term changes in
ene expression mediated by neuroprotective transcription factors
uch as cAMP response element binding protein (CREB) [99]. Given
he recent observations of reduced levels of CSP [90] and of SNARE
omplexes [92] in Alzheimer’s brain samples, this may  be relevant
o the reported therapeutic effects of rolipram [95] and resveratrol
100] in rodent Alzheimer’s models.
. Conclusions
Despite being discovered over 20 years ago, interest in CSP has
ncreased greatly in recent years as a result of compelling evidence
hat it provides a universal neuroprotective role at synapses from
orms to humans. The major mechanism by which CSP prevents
eurodegeneration appears to be maintaining the conformation
f SNAP-25 and thereby facilitating correct SNARE complex for-
ation. However, we currently lack a molecular level description
f how CSP and Hsc70 interact with SNAP-25, how this alters
NAP-25’s conformation to facilitate SNARE complex formation,
nd how this interaction (which presumably can only occur in
lose proximity to the very small number of docked synaptic vesi-
les at the active zone) manages to prevent global degradation of
NAP-25 that mainly localises away from this region. In addition it
eems likely that other client proteins, including dynamin, are also
nvolved, so future genetic and proteomic studies may  illuminate
uch SNAP-25-independent functions of CSP. To date, mutations in
he DNAJC5 gene encoding CSP have only been associated with
NCL, but given the alterations in CSP and SNARE complex lev-
ls in Alzheimer’s disease, future human genetic studies may  wellevelopmental Biology 40 (2015) 153–159 157
reveal additional mutations/polymorphisms associated with other
more common neurodegenerative disorders. Finally, the few stud-
ies reported so far demonstrate that it is possible to compensate
for the lack of CSP with small molecules – further work in this area
may  enable translation of the basic research on CSP performed over
the last 20 years into novel therapies for neurodegeneration.
Acknowledgements
RDB and AM are grateful to the BBSRC, Wellcome Trust, MRC
and AgeUK for funding their research into CSP over many years.
The data presented in Fig. 3 are courtesy of Sudhanva Kahyap.
References
[1] Zinsmaier KE, Hofbauer A, Heimbeck G, Pﬂugfelder GO,  Buchner S, Buchner
E.  A cysteine-string protein is expressed in retina and brain of Drosophila.  J
Neurogenet 1990;7:15–29.
[2] Gundersen CB, Umbach JA. Suppression cloning of the cDNA for a candidate
subunit of a presynaptic calcium channel. Neuron 1992;9:527–37.
[3] Mastrogiacomo A, Parsons SM,  Zampighi GA, Jenden DJ, Umbach JA, Gunder-
sen CB. Cysteine string proteins: a potential link between synaptic vesicles
and  presynaptic Ca2+ channels. Science 1994;263:981–2.
[4] Mastrogiacomo A, Gundersen CB. The nucleotide and deduced amino acid
sequence of a rat cysteine string protein. Brain Res Mol Brain Res 1995;28:
12–8.
[5] Chamberlain LH, Burgoyne RD. Identiﬁcation of a novel cysteine string protein
variant and expression of cysteine string proteins in non-neuronal cells. J Biol
Chem 1996;271:7320–3.
[6] Coppola T, Gundersen C. Widespread expression of human cysteine string
proteins. FEBS Lett 1996;391:269–72.
[7] Gundersen CB, Mastrogiacomo A, Faull K, Umbach JA. Extensive lipidation of
a  Torpedo cysteine string protein. J Biol Chem 1994;269:19197–9.
[8] Gundersen CB, Umbach JA, Mastrogiacomo A. Cysteine-string proteins: a cycle
of  acylation and deacylation. Life Sci 1996;58:2037–40.
[9] Chamberlain LH, Burgoyne RD. The cysteine-string domain of the secretory
vesicle cysteine-string protein is required for membrane targeting. Biochem
J  1998;335(Pt 2):205–9.
[10] van de Goor J, Kelly RB. Association of Drosophila cysteine string proteins with
membranes. FEBS Lett 1996;380:251–6.
[11] Greaves J, Chamberlain LH. Dual role of the cysteine-string domain in
membrane binding and palmitoylation-dependent sorting of the molecular
chaperone cysteine-string protein. Mol  Biol Cell 2006;17:4748–59.
[12] Greaves J, Salaun C, Fukata Y, Fukata M,  Chamberlain LH. Palmitoylation
and membrane interactions of the neuroprotective chaperone cysteine-string
protein. J Biol Chem 2008;283:25014–26.
[13] Gorleku OA, Barns AM,  Prescott GR, Greaves J, Chamberlain LH. Endoplasmic
reticulum localization of DHHC palmitoyltransferases mediated by lysine-
based sorting signals. J Biol Chem 2011;286:39573–84.
[14] Lemonidis K, Gorleku OA, Sanchez-Perez MC,  Grefen C, Chamberlain LH.
The  Golgi S-acylation machinery comprises zDHHC enzymes with major
differences in substrate afﬁnity and S-acylation activity. Mol  Biol Cell
2014;25:3870–83.
[15] Stowers RS, Isacoff EY. Drosophila huntingtin-interacting protein 14 is a
presynaptic protein required for photoreceptor synaptic transmission and
expression of the palmitoylated proteins synaptosome-associated protein 25
and cysteine string protein. J Neurosci 2007;27:12874–83.
[16] Ohyama T, Verstreken P, Ly CV, Rosenmund T, Rajan A, Tien AC, et al.
Huntingtin-interacting protein 14, a palmitoyl transferase required for exo-
cytosis and targeting of CSP to synaptic vesicles. J Cell Biol 2007;179:1481–96.
[17] Braun JE, Scheller RH. Cysteine string protein, a DnaJ family member, is
present on diverse secretory vesicles. Neuropharmacology 1995;34:1361–9.
[18] Chamberlain LH, Henry J, Burgoyne RD. Cysteine string proteins are associated
with chromafﬁn granules. J Biol Chem 1996;271:19514–7.
[19] Pupier S, Leveque C, Marqueze B, Kataoka M,  Takahashi M,  Seagar MJ. Cysteine
string proteins associated with secretory granules of the rat neurohypophysis.
J  Neurosci 1997;17:2722–7.
[20] Evans GJ, Morgan A, Burgoyne RD. Tying everything together: the multi-
ple  roles of cysteine string protein (CSP) in regulated exocytosis. Trafﬁc
2003;4:653–9.
[21] Gorleku OA, Chamberlain LH. Palmitoylation and testis-enriched expression
of  the cysteine-string protein beta isoform. Biochemistry 2010;49:5308–13.
[22] Fernandez-Chacon R, Wolfel M,  Nishimune H, Tabares L, Schmitz F,
Castellano-Munoz M,  et al. The synaptic vesicle protein CSP alpha prevents
presynaptic degeneration. Neuron 2004;42:237–51.
[23] Schmitz F, Tabares L, Khimich D, Strenzke N, de la Villa-Polo P, Castellano-
Munoz M, et al. CSPalpha-deﬁciency causes massive and rapid photoreceptor
degeneration. Proc Natl Acad Sci U S A 2006;103:2926–31.
[24] Kashyap SS, Johnson JR, McCue HV,  Chen X, Edmonds MJ,  Ayala M,  et al.
Caenorhabditis elegans dnj-14, the orthologue of the DNAJC5 gene mutated
in  adult onset neuronal ceroid lipofuscinosis, provides a new platform for
1 ll & D58 R.D. Burgoyne, A. Morgan / Seminars in Ce
neuroprotective drug screening and identiﬁes a SIR-2.1-independent action
of  resveratrol. Hum Mol Genet 2014;23:5916–27.
[25] Braun JE, Wilbanks SM,  Scheller RH. The cysteine string secretory vesicle
protein activates Hsc70 ATPase. J Biol Chem 1996;271:25989–93.
[26] Chamberlain LH, Burgoyne RD. Activation of the ATPase activity of heat-
shock proteins Hsc70/Hsp70 by cysteine-string protein. Biochem J 1997;
322(Pt 3):853–8.
[27] Chamberlain LH, Burgoyne RD. The molecular chaperone function of the
secretory vesicle cysteine string proteins. J Biol Chem 1997;272:31420–6.
[28] Tobaben S, Thakur P, Fernandez-Chacon R, Sudhof TC, Rettig J, Stahl B. A
trimeric protein complex functions as a synaptic chaperone machine. Neuron
2001;31:987–99.
[29] Tobaben S, Varoqueaux F, Brose N, Stahl B, Meyer G. A brain-speciﬁc isoform
of  small glutamine-rich tetratricopeptide repeat-containing protein binds to
Hsc70 and the cysteine string protein. J Biol Chem 2003;278:38376–83.
[30] Leznicki P, High S. SGTA antagonizes BAG6-mediated protein triage. Proc Natl
Acad Sci U S A 2012;109:19214–9.
[31] Wang F, Brown EC, Mak  G, Zhuang J, Denic V. A chaperone cascade sorts
proteins for posttranslational membrane insertion into the endoplasmic
reticulum. Mol  Cell 2010;40:159–71.
[32] Nie Z, Ranjan R, Wenniger JJ, Hong SN, Bronk P, Zinsmaier KE. Overexpression
of  cysteine-string proteins in Drosophila reveals interactions with syntaxin. J
Neurosci 1999;19:10270–9.
[33] Wu  MN, Fergestad T, Lloyd TE, He Y, Broadie K, Bellen HJ. Syntaxin 1A interacts
with multiple exocytic proteins to regulate neurotransmitter release in vivo.
Neuron 1999;23:593–605.
[34] Chamberlain LH, Graham ME,  Kane S, Jackson JL, Maier VH, Burgoyne RD,
et  al. The synaptic vesicle protein, cysteine-string protein, is associated with
the plasma membrane in 3T3-L1 adipocytes and interacts with syntaxin 4. J
Cell  Sci 2001;114:445–55.
[35] Seagar M,  Leveque C, Charvin N, Marqueze B, Martin-Moutot N, Boudier JA,
et  al. Interactions between proteins implicated in exocytosis and voltage-
gated calcium channels. Philos Trans R Soc Lond B Biol Sci 1999;354:
289–97.
[36] Boal F, Zhang H, Tessier C, Scotti P, Lang J. The variable C-terminus of cys-
teine string proteins modulates exocytosis and protein–protein interactions.
Biochemistry 2004;43:16212–23.
[37] Magga JM,  Jarvis SE, Arnot MI,  Zamponi GW,  Braun JE. Cysteine string pro-
tein regulates G protein modulation of N-type calcium channels. Neuron
2000;28:195–204.
[38] Natochin M, Campbell TN, Barren B, Miller LC, Hameed S, Artemyev NO, et al.
Characterization of the G alpha(s) regulator cysteine string protein. J Biol
Chem 2005;280:30236–41.
[39] Sakisaka T, Meerlo T, Matteson J, Plutner H, Balch WE.  Rab-alphaGDI activity
is  regulated by a Hsp90 chaperone complex. EMBO J 2002;21:6125–35.
[40] Miller LC, Swayne LA, Chen L, Feng ZP, Wacker JL, Muchowski PJ, et al. Cys-
teine string protein (CSP) inhibition of N-type calcium channels is blocked by
mutant huntingtin. J Biol Chem 2003;278:53072–81.
[41] Shirasaki DI, Greiner ER, Al-Ramahi I, Gray M,  Boontheung P, Geschwind
DH, et al. Network organization of the huntingtin proteomic interactome in
mammalian brain. Neuron 2012;75:41–57.
[42] Miller LC, Swayne LA, Kay JG, Feng ZP, Jarvis SE, Zamponi GW,  et al. Molec-
ular  determinants of cysteine string protein modulation of N-type calcium
channels. J Cell Sci 2003;116:2967–74.
[43] Leveque C, Pupier S, Marqueze B, Geslin L, Kataoka M,  Takahashi M, et al.
Interaction of cysteine string proteins with the alpha1A subunit of the P/Q-
type calcium channel. J Biol Chem 1998;273:13488–92.
[44] Evans GJ, Morgan A. Phosphorylation-dependent interaction of the synap-
tic  vesicle proteins cysteine string protein and synaptotagmin I. Biochem J
2002;364:343–7.
[45] Boal F, Laguerre M,  Milochau A, Lang J, Scotti PA. A charged prominence in
the linker domain of the cysteine-string protein Cspalpha mediates its regu-
lated interaction with the calcium sensor synaptotagmin 9 during exocytosis.
FASEB J 2011;25:132–43.
[46] Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM,  Sudhof TC. Alpha-
synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell
2005;123:383–96.
[47] Zhang YQ, Henderson MX,  Colangelo CM,  Ginsberg SD, Bruce C, Wu T, et al.
Identiﬁcation of CSPalpha clients reveals a role in dynamin 1 regulation. Neu-
ron 2012;74:136–50.
[48] Rozas JL, Gomez-Sanchez L, Mircheski J, Linares-Clemente P, Nieto-Gonzalez
JL,  Vazquez ME, et al. Motorneurons require cysteine string protein-alpha to
maintain the readily releasable vesicular pool and synaptic vesicle recycling.
Neuron 2012;74:151–65.
[49] Chamberlain LH, Burgoyne RD. Cysteine-string protein: the chaperone at the
synapse. J Neurochem 2000;74:1781–9.
[50] Zinsmaier KE. Cysteine-string protein’s neuroprotective role. J Neurogenet
2010;24:120–32.
[51] Johnson JN, Ahrendt E, Braun JE. CSPalpha: the neuroprotective J protein.
Biochem Cell Biol 2010;88:157–65.
[52] Zinsmaier KE, Eberle KK, Buchner E, Walter N, Benzer S. Paralysis and early
death in cysteine string protein mutants of Drosophila. Science 1994;263:
977–80.
[53] Umbach JA, Zinsmaier KE, Eberle KK, Buchner E, Benzer S, Gundersen
CB.  Presynaptic dysfunction in Drosophila csp mutants. Neuron 1994;13:
899–907.evelopmental Biology 40 (2015) 153–159
[54] Heckmann M,  Adelsberger H, Dudel J. Evoked transmitter release at neuro-
muscular junctions in wild type and cysteine string protein null mutant larvae
of  Drosophila. Neurosci Lett 1997;228:167–70.
[55] Umbach JA, Gundersen CB. Evidence that cysteine string proteins regulate an
early step in the Ca2+-dependent secretion of neurotransmitter at Drosophila
neuromuscular junctions. J Neurosci 1997;17:7203–9.
[56] Morales M,  Ferrus A, Martinez-Padron M.  Presynaptic calcium-channel
currents in normal and csp mutant Drosophila peptidergic terminals. Eur J
Neurosci 1999;11:1818–26.
[57] Ranjan R, Bronk P, Zinsmaier KE. Cysteine string protein is required for cal-
cium secretion coupling of evoked neurotransmission in Drosophila but not
for  vesicle recycling. J Neurosci 1998;18:956–64.
[58] Umbach JA, Saitoe M,  Kidokoro Y, Gundersen CB. Attenuated inﬂux of cal-
cium ions at nerve endings of csp and shibire mutant Drosophila. J Neurosci
1998;18:3233–40.
[59] Dawson-Scully K, Bronk P, Atwood HL, Zinsmaier KE. Cysteine-string protein
increases the calcium sensitivity of neurotransmitter exocytosis in Drosophila.
J  Neurosci 2000;20:6039–47.
[60] Bronk P, Nie Z, Klose MK,  Dawson-Scully K, Zhang J, Robertson RM, et al. The
multiple functions of cysteine-string protein analyzed at Drosophila nerve
terminals. J Neurosci 2005;25:2204–14.
[61] Brown H, Larsson O, Branstrom R, Yang SN, Leibiger B, Leibiger I, et al. Cys-
teine string protein (CSP) is an insulin secretory granule-associated protein
regulating beta-cell exocytosis. EMBO J 1998;17:5048–58.
[62] Chamberlain LH, Burgoyne RD. Cysteine string protein functions directly in
regulated exocytosis. Mol  Biol Cell 1998;9:2259–67.
[63] Zhang H, Kelley WL,  Chamberlain LH, Burgoyne RD, Wollheim CB, Lang J.
Cysteine-string proteins regulate exocytosis of insulin independent from
transmembrane ion ﬂuxes. FEBS Lett 1998;437:267–72.
[64] Graham ME,  Burgoyne RD. Comparison of cysteine string protein (Csp) and
mutant alpha-SNAP overexpression reveals a role for csp in late steps of mem-
brane fusion in dense-core granule exocytosis in adrenal chromafﬁn cells. J
Neurosci 2000;20:1281–9.
[65] Evans GJ, Wilkinson MC,  Graham ME,  Turner KM,  Chamberlain LH, Burgoyne
RD,  et al. Phosphorylation of cysteine string protein by protein kinase A. Impli-
cations for the modulation of exocytosis. J Biol Chem 2001;276:47877–85.
[66] Prescott GR, Jenkins RE, Walsh CM,  Morgan A. Phosphorylation of cysteine
string protein on Serine 10 triggers 14-3-3 protein binding. Biochem Biophys
Res Commun 2008;377:809–14.
[67] Evans GJ, Morgan A. Phosphorylation of cysteine string protein in the brain:
developmental, regional and synaptic speciﬁcity. Eur J Neurosci 2005;21:
2671–80.
[68] Stevens Jr SM,  Zharikova AD, Prokai L. Proteomic analysis of the synaptic
plasma membrane fraction isolated from rat forebrain. Brain Res Mol Brain
Res  2003;117:116–28.
[69] Collins MO, Yu L, Coba MP,  Husi H, Campuzano I, Blackstock WP,  et al. Pro-
teomic analysis of in vivo phosphorylated synaptic proteins. J Biol Chem
2005;280:5972–82.
[70] Evans GJ, Barclay JW,  Prescott GR, Jo SR, Burgoyne RD, Birnbaum MJ, et al.
Protein kinase B/Akt is a novel cysteine string protein kinase that regu-
lates exocytosis release kinetics and quantal size. J Biol Chem 2006;281:
1564–72.
[71] Chiang N, Hsiao YT, Yang HJ, Lin YC, Lu JC, Wang CT. Phosphomimetic mutation
of  cysteine string protein-alpha increases the rate of regulated exocytosis by
modulating fusion pore dynamics in PC12 cells. PLOS ONE 2014;9:e99180.
[72] Garcia-Junco-Clemente P, Cantero G, Gomez-Sanchez L, Linares-Clemente
P,  Martinez-Lopez JA, Lujan R, et al. Cysteine string protein-alpha pre-
vents activity-dependent degeneration in GABAergic synapses. J Neurosci
2010;30:7377–91.
[73] Ruiz R, Casanas JJ, Sudhof TC, Tabares L. Cysteine string protein-alpha is essen-
tial for the high calcium sensitivity of exocytosis in a vertebrate synapse. Eur
J  Neurosci 2008;27:3118–31.
[74] Wishart TM,  Rooney TM,  Lamont DJ, Wright AK, Morton AJ, Jackson M,  et al.
Combining comparative proteomics and molecular genetics uncovers regu-
lators of synaptic and axonal stability and degeneration in vivo. PLoS Genet
2012;8:e1002936.
[75] Ruiz R, Biea IA, Tabares L. alpha-Synuclein A30P decreases neurodegenera-
tion and increases synaptic vesicle release probability in CSPalpha-null mice.
Neuropharmacology 2014;76 Pt A:106–17.
[76] Wang Y, Yu Z, Ren H, Wang J, Wu J, Chen Y, et al. The synergistic effect
between beta-amyloid and alpha-synuclein on the synapses dysfunction in
hippocampal neurons. J Chem Neuroanat 2014;63C:1–5.
[77] Takamori S, Holt M,  Stenius K, Lemke EA, Gronborg M,  Riedel D, et al. Molec-
ular anatomy of a trafﬁcking organelle. Cell 2006;127:831–46.
[78] Wilhelm BG, Mandad S, Truckenbrodt S, Krohnert K, Schafer C, Rammner B,
et  al. Composition of isolated synaptic boutons reveals the amounts of vesicle
trafﬁcking proteins. Science 2014;344:1023–8.
[79] Sharma M,  Burre J, Sudhof TC. CSPalpha promotes SNARE-complex assembly
by chaperoning SNAP-25 during synaptic activity. Nat Cell Biol 2011;13:30–9.
[80] Sharma M, Burre J, Bronk P, Zhang Y, Xu W,  Sudhof TC. CSPalpha knock-
out causes neurodegeneration by impairing SNAP-25 function. EMBO J
2012;31:829–41.
[81] Burgoyne RD, Morgan A. Chaperoning the SNAREs: a role in preventing neu-
rodegeneration. Nat Cell Biol 2011;13:8–9.
[82] Noskova L, Stranecky V, Hartmannova H, Pristoupilova A, Baresova V, Ivanek
R,  et al. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause
ll & DR.D. Burgoyne, A. Morgan / Seminars in Ce
autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am J Hum
Genet 2011;89:241–52.
[83] Benitez BA, Alvarado D, Cai Y, Mayo K, Chakraverty S, Norton J, et al. Exome-
sequencing conﬁrms DNAJC5 mutations as cause of adult neuronal ceroid-
lipofuscinosis. PLoS ONE 2011;6:e26741.
[84] Velinov M,  Dolzhanskaya N, Gonzalez M,  Powell E, Konidari I, Hulme W,  et al.
Mutations in the gene DNAJC5 cause autosomal dominant Kufs disease in a
proportion of cases: study of the Parry family and 8 other families. PLOS ONE
2012;7:e29729.
[85] Cadieux-Dion M,  Andermann E, Lachance-Touchette P, Ansorge O, Meloche C,
Barnabe A, et al. Recurrent mutations in DNAJC5 cause autosomal dominant
Kufs disease. Clin Genet 2013;83:571–5.
[86] Haltia M.  The neuronal ceroid-lipofuscinoses. J Neuropathol Exp Neurol
2003;62:1–13.
[87] Haltia M,  Goebel HH. The neuronal ceroid-lipofuscinoses: a historical intro-
duction. Biochim Biophys Acta 2013;1832:1795–800.
[88] Greaves J, Lemonidis K, Gorleku OA, Cruchaga C, Grefen C, Chamberlain LH.
Palmitoylation-induced aggregation of cysteine-string protein mutants that
cause neuronal ceroid lipofuscinosis. J Biol Chem 2012;287:37330–9.
[89] Zhang YQ, Chandra SS. Oligomerization of cysteine string protein alpha
mutants causing adult neuronal ceroid lipofuscinosis. Biochim Biophys Acta
2014;1842:2136–46.
[90] Tiwari SS, Troakes MDOC, Shurovi BN, Engmann O, Noble W,  Hortobagyi T,
et  al. Evidence that the presynaptic vesicle protein CSPalpha is a key player in
synaptic degeneration and protection in Alzheimer inverted question marks
disease. Mol  Brain 2015;8:6.
[91] Davies MJ, Cooper M,  Perry VH, O’Connor V. Reduced expression of the
presynaptic co-chaperone cysteine string protein alpha (CSPalpha) doesevelopmental Biology 40 (2015) 153–159 159
not exacerbate experimentally-induced ME7 prion disease. Neurosci Lett
2015;589:138–43.
[92] Sharma M,  Burre J, Sudhof TC. Proteasome inhibition alleviates SNARE-
dependent neurodegeneration. Sci Transl Med 2012;4:147ra13.
[93] Baur JA. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing
Dev 2010;131:261–9.
[94] Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, et al. Resveratrol
ameliorates aging-related metabolic phenotypes by inhibiting cAMP phos-
phodiesterases. Cell 2012;148:421–33.
[95] Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M,  Arancio O. Persistent
improvement in synaptic and cognitive functions in an Alzheimer mouse
model after rolipram treatment. J Clin Invest 2004;114:1624–34.
[96] Nikulina E, Tidwell JL, Dai HN, Bregman BS, Filbin MT.  The phosphodiesterase
inhibitor rolipram delivered after a spinal cord lesion promotes axonal
regeneration and functional recovery. Proc Natl Acad Sci U S A 2004;101:
8786–90.
[97] Evans GJ, Morgan A. Regulation of the exocytotic machinery by cAMP-
dependent protein kinase: implications for presynaptic plasticity. Biochem
Soc Trans 2003;31:824–7.
[98] Nagy G, Reim K, Matti U, Brose N, Binz T, Rettig J, et al. Regulation of releasable
vesicle pool sizes by protein kinase A-dependent phosphorylation of SNAP-
25.  Neuron 2004;41:417–29.
[99] Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, et al. Sirt1 mediates
neuroprotection from mutant huntingtin by activation of the TORC1 and CREB
transcriptional pathway. Nat Med  2012;18:159–65.
[100] Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF,  Gibson GE. Dietary
supplementation with resveratrol reduces plaque pathology in a transgenic
model of Alzheimer’s disease. Neurochem Int 2009;54:111–8.
